Archive for the ‘Testing’ Category

Researchers Say New Lyme Test Can Detect Lyme Within 14 Days of Infection

https://www.lymedisease.org/detecting-lyme-within-14-days/

Researchers say this test can detect Lyme within 14 days of infection

Focus on Lyme and Aces Diagnostics Inc. has announced a breakthrough in Lyme disease diagnosis with a new test that detects the disease at all stages, including the crucial first 14 days post-infection, with over 90% accuracy.

Aces Diagnostics is developing and manufacturing this test, aiming for FDA clearance to make it accessible to all patients.

LymeSeek™, developed through a collaboration between Tulane University and Focus on Lyme, combines advanced biomarker research from Tulane’s Monica Embers and nine years of intensive work funded by Focus on Lyme. Enhanced by machine learning, this innovative diagnostic promises to reshape Lyme disease detection.

“Previous tests have been less than 50% accurate, especially in the early stages,” said Tammy Crawford, CEO of Aces Diagnostics. “This has led to countless patients being misdiagnosed or undiagnosed, resulting in prolonged suffering. LymeSeek will change that, providing a reliable diagnostic tool that can save lives.”

Aces Diagnostics Team

The CDC reports that nearly 500,000 people in the U.S. are diagnosed with Lyme disease each year. Globally, 14.5% of the population is affected, with many suffering from chronic symptoms due to delayed diagnosis. A Johns Hopkins study revealed that 38% of Lyme patients continue to experience symptoms six months post-diagnosis, underscoring the need for improved testing.

Simplifying diagnosis

“Current Lyme testing involves multiple steps, with results taking over a week and requiring subjective interpretation,” said Aces Diagnostics Co-Founder Holly Ahern.

“LymeSeek™ will replace this cumbersome process, enabling earlier diagnosis and reducing chronic illness caused by delayed or missed diagnoses.”

Crawford and Ahern are personally invested in this mission, both having daughters who battled Lyme disease. “An early diagnosis could have spared them years of suffering,” said Crawford.

Aces Diagnostics Inc. brings together a team with over 50 years of combined experience in Lyme disease research, backed by a distinguished advisory board that includes experts from Johns Hopkins University, Columbia University, and Tulane University. The company is already advancing development and manufacturing efforts and pursuing early FDA clearance to make LymeSeek™ available to the public by the third quarter of 2026.

SOURCE: Focus on Lyme

______________

**Comment**

Testing has been and continues to be a major problem with Lyme/MSIDS for numerous reasons, one of the biggest being the fact many are coinfected with numerous pathogens that mainstream medicine and research never discuss.  These coinfected patients are some of the sickest but are kicked to the curb because testing doesn’t reveal what’s inside them.

While this new test is a step in the right direction, it still doesn’t address those who have been infected for decades or those who are coinfected.  It’s like comparing apples to oranges and until these issues are addressed, it remains a foreign language to mainstream medicine.

The Johns Hopkins study showing nearly 40% go on to suffer symptoms 6 months post-diagnosis is still low in my opinion due to the fact so many are never diagnosed in the first place and so many are infected with multiple things that are never picked up on testing.

But, one must remain hopeful……

For more:

Category:

Lyme, research, Testing

Scrutinizing Clinical Biomarkers in a Large Cohort of Patients with Lyme Disease and Other Tick-Borne Infections

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893018/

 2024 Feb; 12(2): 380.
Published online 2024 Feb 12. doi: 10.3390/microorganisms12020380
PMCID: PMC10893018
PMID: 38399784

Scrutinizing Clinical Biomarkers in a Large Cohort of Patients with Lyme Disease and Other Tick-Borne Infections

David Xi, Conceptualization, Methodology, Software, Formal analysis, Investigation, Data curation, Writing – original draft, Writing – review & editing, Visualization,1 Kunal Garg, Conceptualization, Methodology, Software, Formal analysis, Investigation, Data curation, Writing – review & editing, Visualization,2 John S. Lambert,1,3,4 Minha Rajput-Ray, Conceptualization, Formal analysis, Investigation, Resources, Writing – review & editing, Supervision,5 Anne Madigan, Conceptualization, Formal analysis, Investigation, Resources, Data curation,1 Gordana Avramovic, Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data curation, Writing – review & editing, Supervision, Project administration,1 and Leona Gilbert, Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data curation, Writing – original draft, Writing – review & editing, Visualization, Supervision, Project administration2,*

Abstract

Standard clinical markers can improve tick-borne infection (TBI) diagnoses. We investigated immune and other clinical biomarkers in 110 patients clinically diagnosed with TBIs before (T0) and after antibiotic treatment (T2). At T0, both the initial observation group and patients without seroconversion for tick-borne pathogens exhibited notably low percentages and counts of CD3 percentage (CD3%), CD3+ cells, CD8+ suppressors, CD4 percentage (CD4%), and CD4+ helper cells, with the latter group showing reductions in CD3%, CD3+, and CD8+ counts in approximately 15-22% of cases. Following treatment at the T2 follow-up, patients typically experienced enhancements in their previously low CD3%, CD3+ counts, CD4%, and CD4+ counts; however, there was no notable progress in their low CD8+ counts, and a higher number of patients presented with insufficient transferrin levels. Moreover, among those with negative serology for tick-borne infections, there was an improvement in low CD3% and CD3+ counts, which was more pronounced in patients with deficient transferrin amounts. Among those with CD57+ (n = 37) and CD19+ (n = 101) lymphocyte analysis, 59.46% of patients had a low CD57+ count, 14.85% had a low CD19 count, and 36.63% had a low CD19 percentage (CD19%). Similar findings were observed concerning low CD57+, CD19+, and CD19% markers for negative TBI serology patients. Overall, this study demonstrates that routine standard clinical markers could assist in a TBI diagnosis.

For more:

Category:

Lyme, research, Testing

IGeneX Lyme ImmunoBlot Test Receives FDA Clearance

https://www.lymedisease.org/lyme-immunoblot-fda-clearance/

IGeneX Lyme ImmunoBlot test receives FDA clearance

The Lyme ImmunoBlot test first introduced by IGeneX in 2017 has now been converted to a test kit–and has received FDA clearance.

The name of the test is iDart™ Lyme IgG ImmunoBlot Kit.

It’s a stand-alone test for the detection of IgG antibodies against Borrelia-causing Lyme disease.

The iDart ImmunoBlot Kit features 31 Lyme antigen bands, which are more antigen bands than any other Lyme immunoblot test on the market.

Moreover, it is the only immunoblot that includes Osp A (P31) and Osp B (P34). (Note: those are the two bands removed from other Lyme tests in the 1990s because of their use in the development of Lyme vaccines.)

The inclusion of 31 antigens improves the sensitivity of the detection of Lyme-specific IgG antibodies, which in turn will improve the sensitivity of the diagnosis of Lyme disease in suspected patients without sacrificing specificity.

“We are delighted to have received FDA clearance for our Lyme ImmunoBlot Kit,” said Dr. Jyotsna Shah, Ph.D., President and Director of IGeneX Labs.

These kits are not available for sale to consumers, but only to labs who perform Lyme diagnostic testing.

Key features of the iDart Lyme IgG ImmunoBlot kit

  • Results interpretation is based upon new criteria and not CDC criteria.
  • The bands are grouped according to their antigen groups. The test is considered positive if the Lyme Screen Antigen (LSA) band and one or more bands from at least two other groups are present on the ImmunoBlot.
  • Bands 31 and 34 are included, making this the only FDA-cleared Lyme serological test that includes these bands.

SOURCE: IGeneX, Inc.

Category:

Activism, Lyme, Testing

More PCR Blunders But Finally Some Justice in Canada

https://popularrationalism.substack.com/p/no-wildlife-is-not-teeming-with-sars?

No, Wildlife is not Teeming with SARS-CoV-2 Virus

A new study claims that wild animals are filled with SARS-CoV-2 virus. Here’s precisely why this is bunk.

JAMES LYONS-WEILER
AUG 14, 2024

The COVID-19 pandemic was met with a high priority on diagnostic testing in managing public health crises. Central to this effort has been the widespread deployment of Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests, widely regarded as the gold standard for detecting SARS-CoV-2.

However, the entire testing enterprise is fraught. As the pandemic has progressed, significant concerns have emerged regarding the reliability of these tests, mainly because unacceptably high cycle thresholds (CT values) are employed. These concerns are not just theoretical—they have profound implications for public health, resource allocation, and, critically, the surveillance of wildlife populations.

RT-PCR testing, though powerful, is inherently limited by its sensitivity to even the smallest fragments of viral RNA from off-target nucleotide sources, such as other viruses or bacteria, or the patient’s or animal’s genome. When CT values exceed 35 cycles, the likelihood of detecting clinically irrelevant, off-target viral fragments increases dramatically, leading to false positives. Such results can misinform public health policies, drive unnecessary quarantines, and, as this critique will argue, skew our understanding of the presence of the virus in wildlife. These issues have been addressed in high technical detail from early 2020 (see articles here, here, and here).

Unfortunately, methods like one published by Ceci et al., 2021 are dangerously lax. The implications of misinterpreting RT-PCR results are far-reaching. In human populations, they can lead to inflated infection rates, misdiagnosed cases, and an exaggerated sense of the virus’s spread. In wildlife studies, these false positives can create a misleading narrative that wildlife species are significant reservoirs of SARS-CoV-2, prompting unnecessary and potentially harmful interventions. As I have pointed out, since early 2020, using high CT values without proper validation, such as sequencing to confirm amplicons, has led to an overestimation of viral prevalence, with severe consequences for science and policy.  (See link for article)

_________________

**Comment**

Weiler’s article dissects flaws in PCR testing in recent studies which are being used to support a narrative that COVID is teeming in wildlife.  I wrote previously about the beloved former president of Tanzania, John Magufuli, RIP, and the fact the man had a PhD in Chemistry.  A bit of a prankster, he punked the WHO and proved the worthlessness of PCR for diagnosing by testing fruit, goats, sheep, and motor oil for COVID.  Nearly half came back positive.  He wouldn’t bow to the ‘powers that be’, went missing and died mysteriously.

It’s also important to remember this test can directly access your brain through CSF and at least two children have died due to injuries caused by COVID PCR tests.

Then there’s the fact that the test swabs used for the PCR test contain the carcinogen ethylene oxide, used to produce chemicals like antifreeze but in smaller quantities is used as a pesticide, which causes cancer, and sterilizing agent in medical settings.  It damages DNA, but the FDA swears it’s safe.

In the Spanish study, “Nanotechnological Investigations on COVID-9 Vaccines: Detection of Toxic Nanoparticles of Graphene Oxide and Heavy Metals,” researchers found graphene oxide in the PCR swabs, masks, and COVID injection vials.

The experimental physicist and biomaterial researcher Dr Antonietta Gatti examined various PCR test rods under the microscope and analyzed their ingredients. The irritating result: the PCR test swabs are made of hard materials and contain a variety of (nano) particles made of silver, aluminium, titanium, glass fibres etc, many of which are undeclared in the package leaflet. When they enter the mucous membrane, they can cause wounds and inflammation, the scientist said. ENT doctors told 2020News  that they are finding more hardened mucous membranes in people who are often tested for SARS-CoV-2. No longer intact mucous membranes can no longer fulfill their task of repelling viruses, bacteria and fungi before they reach the airways, as the pediatrician Eugen Janzen also reports. The germs thus penetrate into the airways without any immune filter.

https://lionessofjudah.substack.com/p/dr-vernon-coleman-how-the-pcr-test?

PCR: Responsible For More Deaths Than Any Test in History

By Dr. Vernon Coleman

8/14/24

The PCR test is responsible for more deaths than any test in history. It was a crucial weapon in misdiagnosing millions of patients. I recently reprinted an article I first wrote three years ago. But there is more to know about the PCR test which I will, in this article, show to be not only worthless but to be responsible for the deaths of millions.

Since the flu of 2019 was selected to be marketed and promoted as a major threat to mankind, and the fake covid pandemic first became a weapon in the manufactured war driving us remorselessly towards Net Zero and the Great Reset, the PCR test has been the weapon of choice for those determined to create fear, to justify pointless and damaging lockdowns, harmful and futile mask wearing and toxic and useless vaccinations.

It was always known that the PCR test didn’t work and wasn’t of any value in detecting the over promoted and oversold version of the annual flu known as covid-19.

Right from the start, the evidence showed that the PCR test was utterly useless in making diagnoses. It was, in fact, worse than useless since it created an epidemic of false positives. No test in history has ever been so misused or used with such malignant intent. And, of course, despite denials there is evidence that the PCR test has killed people. For the evidence please see my article entitled `The PCR Test Can Kill You…’ which was re-published here, on http://www.vernoncoleman.com, just a few days ago.

Everyone who used or promoted the PCR test in the guise of diagnosing covid, or who still uses or promotes the PCR test for that purpose, should be arrested and charged with being part of a conspiracy to deceive, to manipulate and to kill. Anyone who has ever used the PCR test as a diagnostic aid is a criminal and should be regarded as such.  (See link for article)

https://jamesroguski.substack.com/p/justice-in-canada?

Justice in Canada

With help and advice from Chris Weisdorf, Melani Fernando successfully defended her right of bodily autonomy by rejecting the insertion of a nasal swab for a PCR “test” and winning her appeal.

JAMES ROGUSKI
AUG 04, 2024

R. v. Fernando, 2024 ONCJ 336

Excerpts:

Ms. Fernando took an airplane flight to her home in Mississauga, arriving at Pearson Airport on April 9, 2022.  She was apparently vaccinated, but she refused the COVID test, which was randomly selected to be performed on her.

Ms. Fernando was convicted at trial of failing to comply with an order under Section 58 of the Quarantine Act (the “Act”) and fined $5,000 with additional charges, taking it to a fine of $6,255. 

Ms. Fernando appealed to this Court; she was assisted in her appeal by a non-lawyer, Mr. Weisdorf, who was helpful to her and to the Court.

The defence raised an argument before the Justice of the Peace and before me which has merit.  The Justice of the Peace did not address this argument.  The argument, simply put, is that the Act did not authorize a screening officer to use a screening test which involved the entry into the traveller’s body of an instrument or other foreign body.

In my view, a nasal swab is “an instrument” or “foreign body.”  In my view, the Quarantine Act did not permit a screening officer in this case, Mr. Roxas, to require Ms. Fernando to be tested at the airport by insertion into her nasal cavity of a nasal swab.

I do decide that the nasal swab test, which the screening officer in this case required or demanded Ms. Fernando submit to, was an unlawful requirement or demand.  Ms. Fernando’s refusal to comply with the requirement or demand was lawful on her part. 

Because the requirement or demand made of her by the screening officer was not lawful, Ms. Fernando should not have been found guilty by the Justice of the Peace.

I am reversing the Justice of the Peace’s decision and entering a finding of not guilty.

https://canlii.ca/t/k5q3t

(See link for article and videos)

_________________

**Comment**

It’s safe to say nobody should be allowing these toxic swabs to be jammed up their nose.

Further, did you ever ask yourself WHY this is the ONLY test allowed?  You should.

I had to travel over two hours to be able to spit in a vial for a mandatory test before I had a procedure done.  Nobody local offered this test.  They are nearly impossible to find but they exist.  This detail was not made public so few know they have a choice about testing.  This is the CDC’s MO and it was followed in lockstep globally.  Again, lots of money to be made.

I also recommend reading Roguski’s article on Nobel Prize winning scientist, Kary Mullis, the creator of the PCR test who emphatically stated this type of test should NEVER be used to diagnose patients.  The CDC has been using PCR ad nauseum for decades to create ‘pandemics’ that aren’t.  The CDC’s centralization of public health and testing has proved deadly and a threat to national security.  This organization must go as it is beyond hope and rehabilitation.

Mullis was an out-spoken critic and opponent of Dr. Fauci and Big Pharma – and was a constant thorn in their sides.  He conveniently died in Aug. of 2019 of supposed complications from pneumonia right before COVID mania.  Conveniently because had he survived, he would have screamed bloody murder over how COVID has been handled – particularly by using the PCR manufacturing test to inflate cases which even the CDC had to admit few deaths are actually caused by COVID despite hospitals being paid by the federal government to list patients as having COVID, getting tested, being put on a ventilator, and being given remdesivir.

It was a huge money-making racket if you blindly followed government edicts.

Category:

Activism, Testing, Viruses

National Committee Creates New Acronym for Lyme: IACI

Lyme IACI, pronounced “Lyme eye-ACK-ee” is the latest fantasy dreamt up by the National Academies of Sciences, Engineering, and Medicine – the congressionally chartered organization that serves as the ‘collective’ scientific national academy of the U.S., which proudly deploys the climate, health, and equity propaganda pushed by globalists.  The sponsors of the organization are none other than:

AstraZeneca
Burroughs Wellcome Fund
Grantham Foundation
JPB Foundation​
McCall MacBain Foundation
Rockefeller Foundation

Are you getting this yet?

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/

Inquiry to the Deputy Director of the Vector-Borne Diseases Division at the CDC

Carl Tuttle
Hudson, NH, United States
Jul 31, 2024

Notice to everyone who has signed this petition:

The following so-called “National Committee” has been established turning persistent Lyme symptoms into a new acronym: Lyme Infection-Associated Chronic Illness (Lyme IACI)

Medscape

‘Doesn’t Fit Anything I Trained for’: National Committee Examines Treatment for Chronic Illness Following Lyme Disease

https://www.medscape.com/viewarticle/doesnt-fit-anything-i-trained-national-committee-examines-2024a1000dru

So now, Chronic Lyme will be swept under the rug for more decades to come despite the mountain of evidence that we have been dealing with an antibiotic resistant/tolerant superbug!

I don’t think this committee is looking to solve (expose) the chronic Lyme epidemic …. it seems more likely this is an opportunity to exploit the chronically infected with money making pharmaceuticals to treat the symptoms of an antibiotic resistant/tolerant superbug.

“Lyme IACI” conveniently sweeps chronic Lyme under the rug.

Please see the email below addressed to Dr. Ben Beard of the CDC with carbon copy to all members of this committee. I ask that everyone demand a response from Beard. You can copy all email addresses below and send a private email or post a comment to the NASEM Committee’s website: https://www8.nationalacademies.org/pa/feedback.aspx?type=project&key=HMD-HSP-23-07

Inquiry to Ben Beard:

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “cbb0@cdc.gov” <cbb0@cdc.gov>
Cc: “jjohnson@genevausa.org” <jjohnson@genevausa.org>, “theerhisamariee@gmail.com” <theerhisamariee@gmail.com>, “jaucott@jhmi.edu” <jaucott@jhmi.edu>, “cbb0@cdc.gov” <cbb0@cdc.gov>, “jraitt1@stanford.edu” <jraitt1@stanford.edu>, “dclauw@med.umich.edu” <dclauw@med.umich.edu>, “john.leong@tufts.edu” <john.leong@tufts.edu>, “avindra.nath@nih.gov” <avindra.nath@nih.gov>, “charles.chiu@ucsf.edu” <charles.chiu@ucsf.edu>, “elliot.cowan@partnersindiagnostics.com” <elliot.cowan@partnersindiagnostics.com>, “beth.jaworski@nih.hhs.gov” <beth.jaworski@nih.hhs.gov>, “roger@lundquist.org” <roger@lundquist.org>, “rachele.hendricks.sturrup@duke.edu” <rachele.hendricks.sturrup@duke.edu>, “info@lymebiobank.org” <info@lymebiobank.org>, “lorrainejohnson@outlook.com” <lorrainejohnson@outlook.com>, “wendyadams1@gmail.com” <wendyadams1@gmail.com>, “Leith.States@hhs.gov” <Leith.States@hhs.gov>, “tindall.matt@gmail.com” <tindall.matt@gmail.com>, “stacie.hudgens@clinoutsolutions.com” <stacie.hudgens@clinoutsolutions.com>, “raymond_dattwyler@nymc.edu” <raymond_dattwyler@nymc.edu>, “timothy.sellati@globallymealliance.org” <timothy.sellati@globallymealliance.org>, “nklimas@nova.edu” <nklimas@nova.edu>, “kester@genevausa.org” <kester@genevausa.org>, “nicole@nicolemalachowski.com” <nicole@nicolemalachowski.com>, “marcom@genevausa.org” <marcom@genevausa.org>, “stephen.gluckman@pennmedicine.upenn.edu” <stephen.gluckman@pennmedicine.upenn.edu>, “epocratesMedia@athenahealth.com” <epocratesMedia@athenahealth.com>, “epocrates@athenahealth.com” <epocrates@athenahealth.com>
Date: 07/31/2024 7:40 AM EDT
Subject: Inquiry to the Deputy Director of the Vector-Borne Diseases Division at the CDC

Charles B Beard
Deputy Division Director, Division of Vector-Borne Diseases
Centers for Disease Control and Prevention

Dear Dr. Beard,

In 1991 the Lyme disease organism, Borrelia burgdorferi, was grown from the cerebrospinal fluid of patient Vicki Logan at the Centers for Disease Control in Fort Collins, Colorado despite prior treatment with intravenous antibiotics. The patient died when the insurer refused additional IV antibiotics. I have attached a copy of Logan’s positive culture report for your review:

Logan CDC Fort Collins Positive CSF Culture Report (Personal Dropbox storage area)
https://www.dropbox.com/scl/fi/agca4ynn9ok2ykgw6484q/Logan-CDC-Fort-Collins-Positive-CSF-Culture-Report.JPG?rlkey=krhiecm1xdmqs6ubhvjxuzzeo&dl=0

In 1995 the following publication identified treatment-resistant neuroborreliosis:
 
European Neurology 1995
Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104

In 2018 all patients were culture positive even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics. Barbour-Stoener-Kelly (BSK) medium was used and is the same complex medium used in the NIH funded Klempner antibiotic trials.

Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
https://www.mdpi.com/2227-9032/6/2/33

A recently published autopsy study for a young Lyme patient who committed suicide identifies chronic Lyme disease in the patient’s brain which was responsible for his neurological symptoms.

Concurrent Infection of the Human Brain with Multiple Borrelia Species
Published in MDPI Nov. 29, 2023
https://www.mdpi.com/1422-0067/24/23/16906

Excerpt:

The diverse strategies used by spirochetes to avoid the host immune system and persist in the host include active immune suppression, induction of immune tolerance, phase and antigenic variation, intracellular seclusion, changing of morphological and physiological state in varying environments, formation of biofilms and persistent forms, and, importantly, incursion into immune-privileged sites such as the brain. Invasion of immune-privileged sites allows the spirochetes to not only escape from the host immune system but can also reduce the efficacy of antibiotic therapy. 

In addition, there are 700 peer reviewed publications identifying persistent infection and more evidence of seronegative disease.

Question:

As Deputy Director of the Vector-Borne Diseases Division at the CDC, why has all the evidence indicating Borrelia as an antibiotic resistant/tolerant superbug been ignored for decades?

A response to this inquiry is requested.

Please hit reply all when responding.

Carl Tuttle
Hudson, NH

_______________

**Comment**

When reading the Medscape article, please notice the following:

The committee will not make recommendations on specific approaches to diagnosis and treatment when it issues a report in early 2025 but will instead present “consensus findings” on treatment for chronic illness associated with Lyme disease, including recommendations for advancing treatment.

There have been only a few randomized controlled trials (RCTs) conducted on what the committee is calling Lyme Infection-Associated Chronic Illness (Lyme IACI) for now, and no National Institutes of Health (NIH)-funded RCTs in the past 20 years or so. It’s an area void of the US Food and Drug Administration-approved therapies, void of any consensus on the off-label use of medications, and without any current standard of care or proven mechanisms and pathophysiology, said John Aucott, MD, director of the Johns Hopkins Medicine Lyme Disease Clinical Research Center, Baltimore, one of the invited speakers at a public meeting held by the NASEM in Washington, DC, in July.”

The best way to look at this illness is not from the silos of infectious disease or the silos of rheumatology; you have to look across disciplines,” Aucott, also associate professor of medicine in the Division of Rheumatology, told the committee. “The story doesn’t fit anything I trained for in my infectious disease fellowship. Even today, I’d posit that PTLD is like an island — it’s still not connected to a lot of the mainstream of medicine.”

COVID showed the world the devastating impact of ‘consensus-based medicine,’ which a report has deemed ‘shocking and immortal.’ In this Communist-type paradigm doctors are told by bureaucrats how to treat, what they can use to treat, and what they can’t use to treat.  Anything outside the lines of this monolith simply aren’t allowed.  Doctors who dare to think for themselves are persecuted and ostracized – with the full weight of the government pressing down upon them –  often times losing their medical license.

This is the world Lyme literate doctors (LLMDs) have lived in for forty years.

The article also regurgitates that only 10-20% go on to suffer with persistent symptoms after treatment, when the actual percentages are approximately 60% as many are not diagnosed or treated until much later – often years later.

Lyme/MSIDS will never fit into RCTs because there are too many variables to fit into a nice four-cornered research box.  Many never test positive on the CDC-2-tiered testing, many never get an EM rash, numerous coinfections are involved, not to mention the fact there are multiple strains of borrelia that testing will not pick up, and symptoms are wildly variable.  No two patients look alike.

Category:

Activism, Lyme, research, Testing, Treatment